Regenxbio (RGNX) Expands Relationship with AveXix (AVXS) Through Amended License Agreement for Development and Commercialization of Treatments for Spinal Muscular Atrophy

Regenxbio (RGNX) Reports 2017 Year-End Corporate Update

REGENXBIO Inc. (NASDAQ: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today provided a year-end 2017 corporate update.

In 2017, REGENXBIO achieved our key development goals for our lead product candidate programs and expanded our research and development organization and capabilities. We expect to build upon this success in 2018 as we work toward advancing a robust clinical pipeline of product candidates that hold the potential to improve treatment in many diseases, said Kenneth T. Mills, President and Chief Executive... More